Supplementary Online Content


Supplement 1

eMethods. Variant Categorization Based on Clinical Utility

eReferences

eFigure 1. Tumor Whole Exome Sequencing Analysis Pipeline

eFigure 2. Overview of the BASIC3 Clinical Study

This supplementary material has been provided by the authors to give readers additional information about their work.
eMethods. Variant categorization based on clinical utility

We used consensus clinical practice guidelines from expert oncology and pathology committees (National Comprehensive Cancer Network [NCCN], American Society of Clinical Oncology [ASCO], College of American Pathologists), clinical decision-support resources (mycancergenome.org), review of primary literature, and inputs from institutional experts in oncology practice to develop an algorithm for variant ranking based on assessment of clinical utility. Briefly, a database was created with genes and variants categorized into one of four categories (Figure 1A and eTables 3 to 5 in Supplement 2) as follows:

- **Category I** – somatic variants established as diagnostic, prognostic and/or predictive of treatment response in the tumor type being tested, following clinical practice guidelines from NCCN, ASCO or recommendations from the BCM Genomics tumor board, which includes oncologists, geneticists, and molecular pathologists (eTable 3 in Supplement 2). Since this category is tumor-type specific, and pathology tumor diagnoses are often issued in a variable non-controlled vocabulary, this categorization is performed post-hoc by the reviewer during interpretation.

- **Category II** – somatic variants in genes that are members of consensus cancer pathways, targetable gene families, or functional groups/pathways that are targets of either Food and Drug Administration (FDA)-approved or investigational therapeutic agents (eTable 4 in Supplement 2). Variants in this category are not specific for the referenced tumor type being tested, and therefore the clinical utility of such variants is considered ‘potential’ in nature since FDA-approved therapies may not necessarily be applicable in other tumor types. Genes in this list were drawn from several sources, primarily the KEGG (Kyoto Encyclopedia of Genes and Genomes) database for cancer pathways associated with drugs including MAPK pathways (classical, JNK/p38, ERK5), MAPK/STAT/PI3K, PI3K-AKT/mTOR, canonical WNT, VEGF, Hedgehog, and JAK-STAT,1,2 expert-curated consensus cancer pathway genes,3 and recommendations from institutional experts. Classical cancer pathways that did not have any targetable components per KEGG database (e.g., TGF-beta, chromatin modification) were excluded from this category.

- **Category III** – somatic sequence variants in genes of the Wellcome Trust Sanger Institute Cancer Gene Census4,5 and the BCM Genomics Tumor Board (eTable 5 in Supplement 2). Genes in this list include all category 1 and 2 genes along with ~500 additional genes not currently considered to be targetable or belonging to targetable pathways.

- **Category IV** – all other somatic variants.
eReferences
2 KEGG database: Pathways in cancer.
4 COSMIC: catalogue of somatic mutations in cancer.
   http://cancer.sanger.ac.uk/cosmic (accessed April 1, 2015).
A simplified schematic depicting both the sequencing and post-sequencing analytic components of the tumor exome pipeline (see Methods for additional description). The somatic variant list is generated after a subtraction of the normal .vcf from the tumor .vcf following somatic calling parameters (Table S1). Category I to III variants are confirmed by an orthogonal technique (Sanger sequencing) prior to reporting. A multidisciplinary genomics tumor board comprising of oncologists, surgeons, pathologists, genome biologists, and cancer geneticists discuss and review selected patients. QC, Quality control; dbNSFP, database for functional predictions of nonsynonymous SNPs; ESP, Exome Sequencing Project; TG, Thousand Genomes; HGMD, Human Gene Mutation Database; vcf, variant call format; COSMIC, Catalog of Somatic Mutations in Cancer; IGV, Integrative Genomics Viewer; LOH, Loss of heterozygosity.
eFigure 2. Overview of the BASIC3 Clinical Sequencing Study

200 Eligible newly-diagnosed solid tumor patients

50 Excluded (declined participation)

150 Study subjects enrolled

29 No frozen tumor sample available

150 Subjects with blood samples available for WES

121 Subjects with tumor samples available for WES

150 Subjects with blood samples subjected to WES

121 Subjects with tumor samples subjected to WES

150 Subjects with germline WES reports completed

121 Subjects with tumor WES reports completed

© 2015 American Medical Association. All rights reserved.